



Fanconi Cancer Foundation

Strategic Plan 2026–2030

Moonshot Goal: Cure Cancer Without Chemotherapy

CURE

Advance FA Cancer Research and Data Infrastructure

- Translational research pipeline
- Clinical trials advancement
- Shared data infrastructure

CARE

Develop and Disseminate Evidence-Based Cancer Care Guidelines

- Evidence-based clinical guidelines
- Tumor board efficacy and collaboration
- Clinical and community education

COMMUNITY

Empower the FA Community as Strategic Partners

- Advocacy and leadership
- Psychosocial support
- Global partnership

CAPACITY

Grow Transformational Revenue and Partnerships

- Capital campaign execution
- Major gifts growth
- Strategic partnerships

2030 IMPACT

- Non-chemotherapy cancer strategies advancing through clinical trials
- A coordinated global research and data ecosystem supporting FA discovery
- Widely adopted, evidence-based cancer care standards
- An engaged and empowered global FA community shaping research and care
- Sustainable, diversified funding powering continued progress

THE MOONSHOT: CURE CANCER WITHOUT CHEMOTHERAPY

A bold commitment to move beyond chemotherapy by advancing targeted approaches to early detection, prevention, and treatment for cancers associated with Fanconi anemia.

FOUNDATION FOR THE MOONSHOT

Achieving the Moonshot requires scientific discovery, systems, partnerships, and resources. Over the next five years, the Fanconi Cancer Foundation will strengthen financial capacity, organizational infrastructure, and global collaboration to:

- Accelerate translational cancer research pipeline
- Improve FA cancer care and clinical guidance
- Empower the FA community as partners in progress
- Sustain the financial resources required to scale impact

STRATEGIC GOALS (2026–2030)

Focus Area 1: Cure

Advance FA Cancer Research and Data Infrastructure to Enable Non-Chemotherapy Cancer Solutions

Accelerate progress toward safer cancer prevention and treatment strategies for people with Fanconi anemia by strengthening the research ecosystem. This includes funding translational research, supporting early-stage investigators, building partnerships with academic and industry collaborators, and expanding shared data resources that move discoveries into clinical trials.

Strategic priorities

- Build a coordinated translational research pipeline focused on the following priority areas:
 - Chemoprevention
 - Early Detection
 - Gene Therapy
 - FA mouse models
 - Biomarkers
 - Immune exhaustion/inflammation
 - FA and aging
 - Stem cell biology
 - DNA repair
- Launch and expand prevention, early detection, and treatment clinical trials
- Strengthen shared data infrastructure through the FRIENDS data commons
- Support emerging investigators and collaborative research networks
- Develop industry and cooperative research partnerships to accelerate clinical translation

How we will measure progress

- Number of research grants funded annually across translational, clinical, and early-stage investigator categories
- Number of early-stage investigators supported and retained in FA research
- Number of funded projects advancing to next stage (e.g., preclinical → clinical trial)
- Number of clinical trials launched, supported, or influenced by FCF funding or partnerships
- Growth of the FRIENDS data ecosystem:
 - Number of contributing institutions
 - Number of datasets/patient records available for research

- Number of active research and industry partnerships advancing therapeutic development

Success by 2030

- Multiple non-chemotherapy strategies in clinical testing
- A coordinated translational research pipeline of multiple grants focused on DNA repair, immunotherapy, supporting early detection, prevention, and treatment
- A robust global data ecosystem supporting research and clinical trials
- A growing and sustained community of investigators advancing FA cancer research
- Established partnerships accelerating therapeutic development

Focus Area 2: Care

Lead the Development and Dissemination of Evidence-Based Cancer Care Guidelines for Fanconi Anemia

Establish the Fanconi Cancer Foundation as the leader in developing and coordinating evidence-based cancer care guidelines for Fanconi anemia. Through collaboration with clinical experts and researchers, FCF will create, update, and share guidelines and educational resources that support consistent screening, prevention, and care across institutions.

Strategic priorities

- Update and publish comprehensive FA cancer care guidelines
- Expand clinician engagement through virtual tumor boards and expert collaboration
- Translate scientific findings into practical guidance for clinicians
- Develop accessible educational resources for clinicians, individuals with FA, and caregivers
- Align research insights with evolving standards of care

How we will measure progress

- Number of guideline chapters updated and published (cancer and non-cancer)
- Number of clinicians and institutions actively using or accessing guidelines
- Number of tumor board cases reviewed annually (U.S. and Europe)
- Publication on tumor board outcomes and incorporation into clinical guidelines
- Number of clinicians participating in tumor boards and education programs
- Development and distribution of implementation tools:
 - Number of toolkits distributed
 - Number of clinical sites adopting tools
- Number of educational resources produced and translated (including multilingual materials)

- Number of downloads, accesses, or engagements with guideline and education materials

Success by 2030

- Broad adoption of evidence-based cancer care guidelines across institutions treating individuals with FA
- Strong clinician engagement network contribution to continuous improvement standards for FA cancer care
- Improved consistency in screening, prevention, and cancer care for individuals with FA
- Accessible educational resources supporting clinicians and families worldwide

Goal 3: Community

Empower and Elevate the FA Community as a Strategic Partner in Research, Care, Access, and Policy

Strengthen support, advocacy, and engagement across the FA community so individuals with Fanconi anemia, caregivers, clinicians, and researchers can help guide research priorities, improve care, expand therapeutic access, and influence policy. By building trust and leadership within the community, FCF accelerates progress in research, education, awareness, and quality of life.

Strategic priorities

- Strengthen advocacy and leadership pathways within the FA community
- Expand community engagement in research and therapeutic development
- Enhance global collaboration across FA organizations and advocates
- Support psychosocial wellbeing and quality of life
- Elevate the community voice in policy, research, and care

How we will measure progress

- Number of individuals and families engaged annually across programs (retreats, virtual events, advocacy, support services)
- Number of trained community advocates and leaders participating in advocacy initiatives
- Number of community members engaged in research (e.g., advisory roles, study participation, feedback mechanisms)
- Number of partnerships and collaborative initiatives with global FA organizations
- Utilization of psychosocial support services:
 - Number of individuals accessing support programs
 - Participant satisfaction and impact feedback
- Number of educational and community resources developed and accessed

- Documented examples of community input influencing research priorities, care practices, or policy efforts

Success by 2030

- A well-defined global advocacy network advancing FA priorities
- Community perspectives consistently integrated into research, care, and policy efforts
- Expanded access to psychosocial and quality-of-life support across the FA community
- Increased global collaboration among FA organizations and leaders

Goal 4: Capacity

Grow and Sustain Transformational Revenue and Strategic Partnerships to Power the Moonshot

Accelerate revenue growth and expand strategic partnerships to support the Moonshot. Through major gifts, institutional funding, industry collaboration, and diversified philanthropic engagement, FCF will strengthen fundraising infrastructure and ensure sustainable financial growth to support expanded research and global leadership.

Strategic priorities

- Launch and execute a capital campaign
- Expand major gifts and institutional funding
- Build strategic collaborations with industry and research partners
- Grow peer-to-peer and recurring donor programs
- Strengthen development infrastructure and stewardship

How we will measure progress

- Annual revenue growth and diversification across funding streams:
 - Major gifts
 - Institutional funding
 - Industry/pharma partnerships
 - Peer-to-peer and recurring giving
- Progress toward capital campaign goal (total raised and number of major gifts secured)
- Number and value of new major donor relationships established annually
- Growth in recurring donor base (number of donors and total revenue)
- Number and scope of active strategic partnerships (industry, research, nonprofit collaborations such as AACR, ACS)
- Total funding secured through partnerships and collaborative initiatives
- Donor retention and upgrade rates
- Development infrastructure benchmarks (e.g., stewardship touchpoints, pipeline growth)

Success by 2030

- Significant and sustained revenue growth enabling expanded research and program investment
- A fully executed capital campaign supporting long-term strategic priorities
- Established strategic partnerships accelerating research, care, and global impact
- A diversified and resilient fundraising model with strong major gift, institutional, and partnership revenue streams

WHAT SUCCESS LOOKS LIKE BY 2030

The Moonshot represents a bold ambition: curing cancer without chemotherapy. While a cure may take longer, the next five years will build the scientific, clinical, and community infrastructure needed to make that future possible.

By 2030, the Fanconi Cancer Foundation aims to demonstrate measurable progress across Cure, Care, Community, and Capacity.

Research Progress

- Non-chemotherapy prevention or treatment strategies actively tested in clinical trials
- A coordinated translational research pipeline advancing discoveries from laboratory to clinical study
- A strengthened data ecosystem enabling collaborative FA cancer research worldwide

Improvements in Cancer Care

- Updated evidence-based cancer care guidelines informing screening, prevention, and treatment for people with Fanconi anemia
- Expanded clinician engagement through virtual tumor boards and education programs
- Increased consistency in cancer screening and care across participating institutions

A Strong and Engaged Community

- Individuals with Fanconi anemia and caregivers actively shaping research priorities, care strategies, and policy discussions
- Expanded advocacy leadership and global collaboration among FA organizations
- Improved access to psychosocial support and educational resources that support quality of life

Sustainable Growth to Power the Mission

- Sustained growth in philanthropic support and strategic partnerships

- Expanded research investment supporting prevention and treatment breakthroughs
- A diversified fundraising model capable of powering continued progress toward the Moonshot